#407 ‒ Preventing cardiovascular and Alzheimer's disease: lowering LDL early, APOE4, and promising new therapies | Michael Davidson, M.D.

Cardiologist Michael Davidson joins Peter Attia to discuss primary prevention of cardiovascular disease. He argues for targeting causal drivers like LDL early in life and reviews the surprising history of CETP inhibitors—how the HDL-raising hypothesis failed and led to the LDL-lowering drug obicetrapib. They then explore obicetrapib's potential in Alzheimer's prevention, grounded in APOE4 and CETP genetics, and cover the challenges of DHA delivery to the brain, statin–diabetes risk, and the future of clinical trials with AI.